Response to the U.S. Preventative Services Task Force decision on prostate cancer screening

Current Urology Reports

Volumn 14, Issue 3, 2013, Pages 168-173

  Makovey, Iryna ^a   Stephenson, Andrew J ^a   Haywood, Samuel ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Mass screening; Overdiagnosis; Preventive task force; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; LOW RISK POPULATION; MEDICAL DECISION MAKING; ORGANIZATION; PRACTICE GUIDELINE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES; UNITED STATES PREVENTATIVE SERVICES TASK FORCE;

ADVISORY COMMITTEES; DIAGNOSTIC ERRORS; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84878742310     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0318-9     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res. 1980;40:4658-62.
3. Cooperberg MR, Broering JM, Kantoff PW, et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007;178:S14-9.
4. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19:175-81.
5. American Cancer Society. Cancer Facts and Figures 2013. Atlanta, GA: American Cancer Society; 2013.
6. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101:1325-9.
7. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-90.
8. Andriole GL, Crawford ED, Grubb III RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9.
9. Andriole GL, Crawford ED, Grubb III RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32.
10. Pinsky PF, Blacka A, Kramer BS, et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010;7:303-11.
11. Moyer VA. U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-34.
12. Draisma G, De Koning HJ. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003;92 Suppl 2:106-111.
13. Miller AB. New data on prostate-cancer mortality after PSA screening. N Engl J Med. 2012;366:1047-8.
14. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:762-71.
15. Chou R, Dana T, Bougatsos C, et al. Treatments for Localized Prostate Cancer. Systematic Review to Update the 2002 U.S. Preventative Services Task Force Recommendations. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
16. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-32.
17. US Preventive Services Task Force: Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151:716-26, W-236.
18. Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ. 1998;317:559-65.
19. Americal Urologic Association: Prostate-Specific Antigen Best Practice Statement: 2009 Update 2009
20. Zeliadt SB, Hoffman RM, Etzioni R, et al. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011;103:520-3.
21. • Volk RJ, Linder SK, Kallen MA, et al. Primary care physicians' use of an informed decision-making process for prostate cancer screening. Ann Fam Med. 2013;11:67-74. This is an interesting and important paper that will hopefully lead to more literature of this kind. It is important to examine how the recommendations will affect the practice of medicine and whether, in fact, PSA screening will be affected, as well as prostate cancer treatment and outcomes.
22. So C, Kirby KA, Mehta K, et al. Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy. J Gen Intern Med. 2012;27:653-60.
23. Drazer MW, Huo D, Schonberg MA, et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011;29:1736-43.
24. Scosyrev E, Wu G, Golijanin D, et al. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int. 2012;110:1485-90.
25. Holmstrom B, Johansson M, Bergh A, et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ. 2009;339:b3537.
26. Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007;25:431-6.
27. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268-78.
28. • Ulmert D, Cronin AM, Bjork T et al: Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 2008;6:6-7015-6-6. This is an important study that demonstrates a possible smart application of PSA, as opposed to generalized screening. This suggests that perhaps we can indeed fine tune our screening protocols and limit them to patients who would actually benefit from diagnosis.
29. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010;341:c4521.
30. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-31.
31. Miocinovic R, Jones JS, Pujara AC, et al. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology. 2011;77:980-4.
32. • Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-13. This is an important study since it demonstrates that patients with localized prostate cancer can be observed as opposed to treated and, thus, can avoid a number of complications that are associated with aggressive treatment options. This also can mean that it is not the screening that should be limited but, perhaps, the treatment should become more selective. This would address the USPTS concerns regarding the moderate harm that is associated with treatment, and not the screening itself.